Literature DB >> 2257205

A randomised study comparing intermittent to continuous administration of magnesium aspartate hydrochloride in cisplatin-induced hypomagnesaemia.

E E Vokes1, R Mick, N J Vogelzang, R Geiser, F Douglas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2257205      PMCID： PMC1971562          DOI： 10.1038/bjc.1990.429

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  14 in total

1.  The magnesium-deficiency tetany syndrome in man.

Authors:  B L VALLEE; W E WACKER; D D ULMER
Journal:  N Engl J Med       Date:  1960-01-28       Impact factor: 91.245

Review 2.  Toxic effects of cis-dichlorodiammineplatinum(II) in man.

Authors:  D D Von Hoff; R Schilsky; C M Reichert; R L Reddick; M Rozencweig; R C Young; F M Muggia
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

Review 3.  Drugs five years later. Cisplatin.

Authors:  P J Loehrer; L H Einhorn
Journal:  Ann Intern Med       Date:  1984-05       Impact factor: 25.391

4.  Magnesium homeostasis following chemotherapy with cisplatin: a prospective study.

Authors:  A F Stewart; T Keating; P E Schwartz
Journal:  Am J Obstet Gynecol       Date:  1985-11-15       Impact factor: 8.661

5.  Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin.

Authors:  R L Schilsky; T Anderson
Journal:  Ann Intern Med       Date:  1979-06       Impact factor: 25.391

6.  Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin.

Authors:  N J Vogelzang; J L Torkelson; B J Kennedy
Journal:  Cancer       Date:  1985-12-15       Impact factor: 6.860

7.  Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer.

Authors:  R L Schilsky; A Barlock; R F Ozols
Journal:  Cancer Treat Rep       Date:  1982-09

Review 8.  Renal and electrolyte disturbances associated with cisplatin.

Authors:  J D Blachley; J B Hill
Journal:  Ann Intern Med       Date:  1981-11       Impact factor: 25.391

9.  Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin.

Authors:  M Lam; D J Adelstein
Journal:  Am J Kidney Dis       Date:  1986-09       Impact factor: 8.860

10.  Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man.

Authors:  M Dentino; F C Luft; M N Yum; S D Williams; L H Einhorn
Journal:  Cancer       Date:  1978-04       Impact factor: 6.860
View more
  8 in total

Review 1.  Drug-induced hypomagnesaemia : scope and management.

Authors:  Jacob Atsmon; Eran Dolev
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  Evaluation of intervention to prevent hypomagnesemia in cervical cancer patients receiving combination cisplatin and radiation treatment.

Authors:  Rodney J Hunter; Makala B Pace; Kimberly A Burns; Catherine C Burke; Deborah A Gonzales; Nicki F Webb; Charles F Levenback; Anuja Jhingran; Crystal Parker; Mark F Munsell; Judith A Smith
Journal:  Support Care Cancer       Date:  2009-01-27       Impact factor: 3.603

3.  Influence of magnesium and parathyroid hormone on cisplatin-induced nephrotoxicity in esophageal squamous cell carcinoma.

Authors:  Hirotaka Konishi; Hitoshi Fujiwara; Hiroshi Itoh; Atsushi Shiozaki; Tomohiro Arita; Toshiyuki Kosuga; Ryo Morimura; Shuhei Komatsu; Daisuke Ichikawa; Kazuma Okamoto; Eigo Otsuji
Journal:  Oncol Lett       Date:  2017-11-03       Impact factor: 2.967

4.  Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection.

Authors:  Yasuhiro Kidera; Hisato Kawakami; Tsutomu Sakiyama; Kunio Okamoto; Kaoru Tanaka; Masayuki Takeda; Hiroyasu Kaneda; Shin-ichi Nishina; Junji Tsurutani; Kimiko Fujiwara; Morihiro Nomura; Yuzuru Yamazoe; Yasutaka Chiba; Shozo Nishida; Takao Tamura; Kazuhiko Nakagawa
Journal:  PLoS One       Date:  2014-07-14       Impact factor: 3.240

5.  Effect of Oral Magnesium Oxide Supplementation on Cisplatin-Induced Hypomagnesemia in Cancer Patients: A Randomized Controlled Trial.

Authors:  Maryam Zarif Yeganeh; Masoud Vakili; Ali Shahriari-Ahmadi; Marzieh Nojomi
Journal:  Iran J Public Health       Date:  2016-01       Impact factor: 1.429

6.  Case Report and Supporting Documentation: Acute Kidney Injury Manifested as Oliguria Is Reduced by Intravenous Magnesium Before Cisplatin.

Authors:  Mary Elizabeth Money; Aghiles Hamroun; Yan Shu; Carolyn Matthews; Sara Ahmed Eltayeb; Giuliano Ciarimboli; Christine Noel Metz
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

7.  Severe intracellular magnesium and potassium depletion in patients after treatment with cisplatin.

Authors:  H Lajer; H Bundgaard; N H Secher; H H Hansen; K Kjeldsen; G Daugaard
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

8.  Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer.

Authors:  Takahiro Kimura; Taijiro Ozawa; Nobuhiro Hanai; Hitoshi Hirakawa; Hidenori Suzuki; Hiroshi Hosoi; Yasuhisa Hasegawa
Journal:  J Otolaryngol Head Neck Surg       Date:  2018-02-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.